Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation

Currently, more and more patients receive first-line treatment with immunotherapy combinations and not all patients respond in metastatic renal cell carcinoma. After IO-IO progression, we don’t have a standard of treatment because it is not available prospective data on this setting. We present the...

Descripción completa

Detalles Bibliográficos
Autores principales: Molina-Cerrillo, Javier, Alonso-Gordoa, Teresa, Carrato, Alfredo, Grande, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275785/
https://www.ncbi.nlm.nih.gov/pubmed/32547710
http://dx.doi.org/10.18632/oncotarget.27598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275785/
https://www.ncbi.nlm.nih.gov/pubmed/32547710
http://dx.doi.org/10.18632/oncotarget.27598

Ejemplares similares